Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
First quarter financial results. For the first quarter of fiscal year (FY) 2026, AZZ reported adjusted net income of $53.8 million or $1.78 per share compared to $44.0 million or $1.46 per share during the prior year period and our estimate of $50.1 million or $1.66 per share. Compared to the first quarter of FY 2025, sales increased 2.1% to $422.0 million. Adjusted EBITDA increased 13.1% to $106.4 million, representing 25.2% of sales compared to 22.8% of sales during the prior year period.
Updating estimates. We have increased our FY 2026 EBITDA and EPS estimates to $388.3 million and $6.00, respectively, from $381.7 million and $5.83. In FY 2026, our estimates reflect average gross margins of 30.0% and 20.3% for the Metal Coatings and Precoat Metals segments, respectively. Moreover, we have published our estimates for 2027 through 2031 in the back of this report. Our forward estimates reflect an average 30.5% gross margin as a percentage of sales for the Metal Coatings segment, compared to the prior average of 28.0%. The average gross margin as a percentage of sales for the Precoat Metals business is unchanged at 20.3%.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
In an unexpected fiscal twist, the U.S. Treasury reported a $27 billion surplus in June — the first time in years the federal government has posted black ink for this particular month. Driving the surprise? A surge in customs duties fueled by newly imposed tariffs under President Donald Trump’s aggressive trade agenda.
The surplus, while modest compared to the year’s broader budget picture, stands in stark contrast to the $316 billion deficit recorded in May. More importantly, it signals how tariff policy is beginning to influence federal revenues in meaningful ways, even as concerns about growing debt and interest costs remain front and center.
The most striking data point from the report was the $27 billion in customs duties collected during June — a 301% increase compared to June 2024. The revenue bump is largely attributed to Trump’s across-the-board 10% tariffs enacted in April, along with a broader set of reciprocal tariffs targeting specific trade partners.
So far this fiscal year, tariff collections have reached $113 billion, an 86% increase year-over-year. These revenues are helping to temporarily offset the impact of broader fiscal challenges, including persistently high debt servicing costs and increased spending in select areas.
This spike in duties comes as negotiations continue with several of America’s largest trading partners. While some sectors — particularly manufacturing and agriculture — have expressed concern about long-term consequences, the short-term impact on federal finances is undeniable.
The June surplus wasn’t only about tariffs. Total federal receipts rose 13% year-over-year, while outlays declined by 7%. Adjusted for calendar shifts, the month would have otherwise shown a $70 billion deficit — still an improvement, but a reminder that structural deficits remain.
Year-to-date, government receipts are up 7%, outpacing the 6% growth in spending. However, the fiscal year deficit still stands at $1.34 trillion with three months remaining, reflecting broader trends that include rising entitlement costs and major legislative spending.
Despite the June surplus, one area of spending continues to cast a long shadow: interest on the national debt. Net interest payments reached $84 billion in June — higher than any other spending category except Social Security. For the fiscal year so far, the U.S. has paid $749 billion in net interest, with projections pointing toward a staggering $1.2 trillion in interest payments by year-end.
These figures highlight the growing burden of servicing the nation’s $36 trillion debt, especially as Treasury yields remain elevated. While Trump has pressured the Federal Reserve to cut interest rates — a move that would help reduce the cost of borrowing — Chair Jerome Powell has signaled caution, particularly given the potential inflationary effects of the new tariffs.
The June surplus provides a rare moment of good news for Washington’s balance sheet, but it may not signal a lasting trend. Much of the improvement stems from one-time revenue boosts and calendar effects. Long-term fiscal stability will still depend on broader policy decisions around spending, entitlement reform, and economic growth.
That said, the recent uptick in tariff-related revenues highlights how trade policy — often viewed primarily through an economic or geopolitical lens — can play an important role in shaping government finances.
If tariff collections continue to surge, they may provide more than just leverage in trade talks — they could also help bridge some of the budget gap. But as with all policy tools, the question remains: at what cost?
Silver prices surged to their highest level since 2011 this week, fueled by rising premiums in the U.S., tight physical supply in London, and increasing industrial demand. The white metal climbed as high as $37.59 per ounce in the spot market, with U.S. futures contracts pushing toward $38.46—an unusually large gap that signals growing pressure in the global silver supply chain.
This recent rally underscores silver’s unique status as both a monetary asset and a critical industrial material, especially in sectors tied to clean energy. Up more than 27% year-to-date, silver has begun to outpace gold and other precious metals, attracting the attention of traders, long-term investors, and industrial buyers alike.
One of the more telling developments this week is the growing dislocation between the London spot price and U.S. futures contracts. Typically, such discrepancies are short-lived as traders use arbitrage to align prices. But this time, the gap is persisting—indicating logistical constraints and a tightening supply chain.
The root of this premium appears to stem from earlier in the year, when U.S. tariff threats on silver imports spurred a surge in futures prices. That sparked a rush to secure physical metal for delivery to New York’s COMEX warehouses. While the White House later confirmed that bullion would not be exempt from tariffs, the resulting outflow drained accessible inventories.
According to Daniel Ghali of TD Securities, the silver floating in the market is now at record lows. LBMA silver’s free-float has reached its lowest levels in recorded history, with analysts emphasizing that a physical squeeze may be necessary to rebalance the market.
Another warning sign: borrowing costs for silver in London have surged. The one-month implied lease rate jumped to an annualized 4.5% on Friday—well above its usual near-zero levels. This is a clear indicator that silver in London is becoming harder to access, particularly for short sellers and industrial users that rely on short-term lending of physical silver.
Much of London’s silver is held by exchange-traded funds (ETFs), which are not easily available for lending. Bloomberg data shows a 1.1 million ounce inflow into silver-backed ETFs on Thursday alone. While this is good news for long-term investors, it exacerbates near-term scarcity for traders seeking physical delivery.
Silver’s recent surge is also being driven by robust demand from both sides of its identity: as a safe-haven asset and as an industrial input. Its role in clean energy—especially in photovoltaic solar panels—has elevated silver’s strategic importance. According to the Silver Institute, the market is now in its fifth consecutive annual deficit.
As the world pushes further into renewable energy technologies, demand for silver in solar, EVs, and advanced electronics is expected to accelerate.
With inventory levels falling, premiums rising, and industrial demand growing, silver’s bullish outlook appears to be more than a short-term spike. If market dislocations persist and supply tightness continues, silver could enter a new phase of price discovery—driven as much by fundamentals as by financial flows.
Investors would be wise to watch the $40 level as the next psychological milestone. And if the physical squeeze intensifies, we may be entering a new era for this historically underappreciated metal.
U.S. airline stocks took flight on Thursday after Delta Air Lines (NYSE: DAL) posted quarterly earnings that beat expectations, signaling a potential rebound for a sector that’s struggled amid tariff-related uncertainty and shifting consumer behavior.
Delta’s upbeat results ignited a broad rally, with shares of American Airlines (AAL) and United Airlines (UAL) surging more than 11%, and Southwest Airlines (LUV) and Alaska Air (ALK) climbing over 5% and 8%, respectively. The rally comes after months of cautious sentiment in the travel sector, with many carriers pulling back 2025 forecasts in response to global economic uncertainty and weaker forward bookings.
Delta’s Q2 results provided a much-needed dose of optimism. The company reported adjusted revenue of $15.5 billion and earnings per share (EPS) of $2.10—narrowly beating Wall Street expectations. Operating income hit $2 billion, with a 13.2% margin, slightly below last year’s 14.7% but still robust in a challenging environment.
Crucially, Delta said booking activity had stabilized, offering reassurance that passenger demand is holding steady despite consumer jitters related to trade policy. Premium ticket revenue rose 5% year over year, and loyalty program revenue climbed 8%—a strong sign that high-value travelers remain engaged.
Delta’s CEO Ed Bastian struck an optimistic tone, stating, “As we look to the second half of our centennial year, we remain focused on executing our strategic priorities and managing the levers within our control to deliver strong earnings and cash flow.”
The momentum quickly spread across the industry. Investors appeared encouraged that Delta’s success could be a bellwether for other major carriers, all of which are slated to report earnings in the next two weeks. With oil prices down significantly—a critical cost input for airlines—there is growing belief that airlines could outperform expectations in the second half of the year.
Delta reported an 11% year-over-year drop in fuel expenses, driven by a 14% reduction in its per-gallon price. That trend is expected to benefit peers like United, American, and Southwest as they release their financials.
Deutsche Bank analysts noted that United and American are both poised to beat consensus earnings, with regional and niche carriers like Sun Country (SNCY) and SkyWest (SKYW) also showing potential for outperformance.
After a rough start to the year marked by economic headwinds, regulatory uncertainty, and supply chain pressures, Thursday’s surge in airline stocks may signal the start of a recovery phase. While risks remain—including volatile energy prices, evolving travel patterns, and the impact of trade policies—Delta’s performance shows that airlines with diversified revenue streams and efficient operations can still thrive.
Investors will be watching closely as earnings from other carriers roll in. If they echo Delta’s results and reintroduce full-year guidance, it could further boost confidence in the sector—and signal clear skies ahead for airline investors
RESTON, Va., July 10, 2025 /PRNewswire/ — V2X, Inc., (NYSE: VVX), a leading provider of global mission solutions, will report second quarter 2025 financial results on Monday, August 4, 2025, after market close. Senior management will conduct a conference call at 4:30 p.m. ET that same day.
U.S.-based participants may dial in to the conference call at 877-300-8521, while international participants may dial 412-317-6026. A live webcast of the conference call as well as an accompanying slide presentation will be available at https://app.webinar.net/MPvl2xBdpg3 and on the Investors section of the V2X website at https://gov2x.com/.
A replay of the conference call will be posted on the V2X website shortly after completion of the call and will be available for one year. A telephonic replay will also be available through August 18, 2025, at 844-512-2921 (domestic) or 412-317-6671 (international) with passcode 10200918.
About V2X V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.
Investor Contact Mike Smith, CFA Vice President, Treasury, Corporate Development and Investor Relations IR@goV2X.com 719-637-5773
Media Contact Angelica Spanos Deoudes Director, Corporate Communications Angelica.Deoudes@goV2X.com 571-338-5195
RICHMOND, Va.–(BUSINESS WIRE)– Lucky Strike Entertainment (NYSE: LUCK), one of the world’s premier Owner/Operators of location-based entertainment, has taken a major step forward in its long-term growth strategy with the acquisition of the real estate underlying 58 locations. Lucky Strike is the current operator of each location and will remain so following the close of the transaction. The $306 million acquisition transforms the Company’s cost structure by reducing annual rent obligations and unlocking powerful financial and operational flexibility. Previously leased, these high-traffic locations generated approximately $80 million in annualized EBITDAR against $21 million in rent obligations (subject to 15% escalations every five years). By transitioning from renter to owner on existing Company venues, Lucky Strike captures immediate value, eliminates future lease inflation risk, and strengthens control over strategic assets in key markets.
“By acquiring the real estate underlying these 58 existing locations, we maximize our flexibility to optimize our capital structure and location footprint,” said Bobby Lavan, Chief Financial Officer. “As we continue to make progress in our business, this transaction provides incremental opportunities to drive deleveraging in the short and medium term. The purchase price highlights the long-term attractiveness of the stable and growing cash flows of our individual locations. The transaction is immediately accretive to earnings and cash flow and positions us to continue reinvesting in our most profitable venues and initiatives.”
The acquisition was financed through a $230 million bridge facility, availability under Lucky Strike’s revolving credit line, and cash on hand. The transaction is expected to be deleveraging and demonstrates a disciplined capital deployment strategy with a focus on high-ROI outcomes that increase optionality.
Spanning 16 states, the 58-property portfolio includes prime locations in California, Illinois, Georgia, Arizona, and Colorado—markets where the Company has a demonstrated track record of operational excellence and strong customer demand. Transitioning to full ownership of these properties enables Lucky Strike to further optimize its earnings base on a granular, market-by-market basis, while providing a foundation for long-term strategic growth and enhanced capital allocation.
This transaction reflects Lucky Strike’s continued momentum, strong balance sheet, and commitment to creating enduring value for its shareholders.
About Lucky Strike Entertainment
Lucky Strike Entertainment is one of the world’s premier location-based entertainment platforms. With over 360 locations across North America, Lucky Strike Entertainment provides experiential offerings in bowling, amusements, water parks, and family entertainment centers. The Company also owns the Professional Bowlers Association, the major league of bowling and a growing media property that boasts millions of fans around the globe. For more information on Lucky Strike Entertainment, please visit IR.LuckyStrikeEnt.com.
Madrid, Spain, July 10, 2025 – (GLOBE NEWSWIRE) Codere Online (Nasdaq: CDRO / CDROW, the “Company”), a leading online gaming operator in Spain and Latin America, today announced that the Codere brand1 has improved its position to 77th, up from 85th in 2024, in a ranking of Spain’s most valuable brands, according to Brand Finance.
Codere remains the only gaming brand on the list, marking its leadership in the sector, and maintains its record of consistently being named on the Top 100 list since 2010, putting it alongside household names such as Zara, Vueling and Movistar as titans in Spanish business.
The last year has seen Codere Online continue to expand in its core markets of Spain and Mexico, as well as leverage partnerships with footballing giants Real Madrid and C.F. Monterrey to further boost its brand awareness, including activations around the FIFA Club World Cup.
Alberto Telias, Chief Marketing Officer of Codere Online, said: “Our marketing and sponsorship efforts over the last 12 months have been reflected in the consolidation of our status as a market leading brand in Spain. We’re proud of the experiences we offer our customers, that truly allow them to connect with the Codere brand.”
Codere Online started operations in Spain in 2014. In the twelve months ended March 31, 2025, the Company generated more than 87 million euros of net gaming revenue in Spain, with more than 50,000 average monthly active players in the country.
About Codere Online Codere Online refers, collectively, to Codere Online Luxembourg, S.A. and its subsidiaries. Codere Online launched in 2014 as part of the renowned casino operator Codere Group. Codere Online offers online sports betting and online casino through its state-of-the art website and mobile applications. Codere currently operates in its core markets of Spain, Mexico, Colombia, Panama and Argentina. Codere Online’s online business is complemented by Codere Group’s physical presence in Spain and throughout Latin America, forming the foundation of the leading omnichannel gaming and casino presence.
About Codere Group Codere Group is a multinational group devoted to entertainment and leisure. It is a leading player in the private gaming industry, with four decades of experience and with presence in seven countries in Europe (Spain and Italy) and Latin America (Argentina, Colombia, Mexico, Panama, and Uruguay).
Contacts:
Investors and Media Guillermo Lancha Director, Investor Relations and Communications Guillermo.Lancha@codere.com (+34) 628 928 152
1 Pursuant to the terms of a relationship and license agreement, Codere Group granted Codere Online a license to use certain “Codere” trademarks.
TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against mpox and rabbitpox (more than one year) in animals
Subcutaneous administration of TNX-801 yielded equivalent protection to the traditional percutaneous administration
CHATHAM, N.J., July 10, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the presentation of new findings on TNX-801 (recombinant horsepox, live virus vaccine) at the Vaccine Congress 2025 in Vienna on July 10, 2025, by Sina Bavari, PhD, Executive Vice President, Infectious Disease Research and Development.
“The data show that TNX-801 can deliver durable immunity while remaining highly attenuated, a balance that sets it apart from earlier orthopox vaccines,” said Seth Lederman, MD, Chief Executive Officer of Tonix Pharmaceuticals. “The novel finding that subcutaneous (s.c.) administration of TNX-801 provides equivalent protection to percutaneous administration, is leading us to develop the s.c. product first. Most live-virus vaccines are delivered s.c. and this route of administration has further potential benefits of decreased administration-site bacterial superinfection, scarring, or inadvertent transfer to other body sites by itching. We believe TNX-801 has the potential to become a critical tool for containing mpox and preparedness against the malicious reintroduction of smallpox. We look forward to advancing TNX-801 into the clinic by s.c. delivery.”
TNX-801 is a recombinant horsepox-derived vaccine candidate designed to prevent orthopox viruses and provide durable humoral and cellular immunity from a single dose. In primary human dermal cells, the virus replicates twenty-seven to one-hundred-nineteen-fold less than licensed vaccinia strains, and in interferon receptor knockout mice it is up to one-hundred-thousand-fold less virulent than those legacy vaccines. Preclinical studies further showed that a single dose of TNX-801 produced strong binding and neutralizing antibody responses across mice, rabbits, hamsters, and cynomolgus macaques, including immunocompromised animals. All vaccinated macaques survived lethal Clade I mpox challenge without lesions, and rabbit models remained fully protected for fourteen months.
“Our data show that TNX-801 delivers durable immunity without safety concerns of live virus vaccines,” said Dr Bavari. “TNX-801 dissociates immune protection from some of the side-effects associated with traditional vaccinia-based vaccines and potentially offers a unique risk-benefit profile for mpox and smallpox prevention. We are excited to advance this program toward clinical evaluation in collaboration with public-health partners worldwide.”
The World Health Organization and the Centers for Disease Control and Prevention continue to classify mpox as an ongoing public-health concern. A single-dose vaccine with the attenuation and immunogenicity profile demonstrated by TNX-801 could streamline outbreak response by reducing the need for approved multi-visit immunization schedules.
Tonix Pharmaceuticals Holding Corp.* Tonix is a fully-integrated biotech company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix’s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4200 for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years. TNX-4200 is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.
* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners. This press release and further information about Tonix can be found at www.tonixpharma.com.
Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Zembrace® SymTouch® (sumatriptan succinate) injection (Zembrace) and Tosymra® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.
Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.
Important Safety Information
Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:
discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back
severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
pain or discomfort in your arms, back, neck, jaw or stomach
shortness of breath with or without chest discomfort
breaking out in a cold sweat
nausea or vomiting
feeling lightheaded
Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.
Do not use Zembrace or Tosymra if you have:
history of heart problems
narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)
uncontrolled high blood pressure
hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.
had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation
severe liver problems
taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.
are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.
an allergy to sumatriptan or any of the components of Zembrace or Tosymra
Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.
Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.
Zembrace and Tosymra may cause serious side effects including:
changes in color or sensation in your fingers and toes
sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever
cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet
increased blood pressure including a sudden severe increase even if you have no history of high blood pressure
medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.
serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.
hives (itchy bumps); swelling of your tongue, mouth, or throat
seizures even in people who have never had seizures before
The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only).
Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider.
This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.
You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Bitcoin has once again captured the spotlight after smashing through the $112,000 mark this week—its first all-time high since May 2025. This milestone solidifies the cryptocurrency’s remarkable comeback and affirms its growing relevance in mainstream finance. As of Thursday morning, BTCUSD is trading slightly below its record, consolidating gains while traders and investors alike look ahead to what’s next.
The digital asset’s latest rally is driven by a combination of favorable technicals, strengthening institutional demand, and a more constructive policy environment in the U.S. That’s an increasingly powerful trifecta in a year where markets have otherwise been defined by policy uncertainty and choppy economic data.
Technically, Bitcoin has broken above the top of a descending channel it’s been trading in since late May. This kind of breakout is often viewed as a bullish continuation signal, suggesting the uptrend that started earlier in the year may still have room to run.
Momentum indicators such as the Relative Strength Index (RSI) remain strong but not yet overbought, implying the rally could continue without immediate risk of a pullback. A widely used forecasting technique known as the measuring principle places Bitcoin’s next major upside target near $146,400, suggesting a potential 30% gain from current levels.
Fundamentally, Bitcoin’s breakout is underpinned by a steady stream of positive developments. Notably, more corporations have begun adding Bitcoin to their balance sheets—signaling long-term belief in its value as a hedge or store of wealth. Meanwhile, lawmakers in Washington are making progress on bipartisan crypto legislation aimed at providing regulatory clarity, particularly around digital asset custody and taxation.
Additionally, the rise of spot Bitcoin ETFs continues to attract institutional money that might otherwise avoid crypto exchanges. While trading volumes on platforms like Coinbase remain muted, demand through custodial services and ETFs is on the rise—a sign that “quiet accumulation” is likely underway.
Bitcoin is up nearly 19% year-to-date, a performance that puts it in line with top-performing tech stocks like Microsoft and Nvidia. For many investors, this reinforces the asset’s appeal as a digital growth play with asymmetric upside potential.
While the medium- and long-term outlook remains bullish, investors should keep an eye on near-term support. The$107,000level, just under the breakout trendline and 50-day moving average, could serve as the first key floor during any pullbacks.
A break below that might open the door for a retest of the psychological$100,000 level, which coincides with a dense area of price action from late 2024 and early 2025.
Bitcoin’s new all-time high marks more than just a number—it reflects growing maturity in the asset class. Whether you’re a long-term believer or a tactical trader, the setup ahead presents both opportunity and risk. But for now, Bitcoin’s breakout confirms what many in the crypto space have long expected: the next chapter of mainstream adoption is already underway.
Madrid, Spain and Tel Aviv, Israel, July 10, 2025 (GLOBE NEWSWIRE) – Codere Online Luxembourg, S.A. (Nasdaq: CDRO / CDROW) (the “Company” or “Codere Online”) a leading online gaming operator in Spain and Latin America, today announced that it will release its second quarter 2025 results prior to 8:30AM US Eastern Time on July 31, 2025.
At 8:30AM US Eastern Time on the same day, Codere Online’s management will host a conference call to discuss the results and provide a business update.
The Company’s earnings press release and related materials will be available on Codere Online’s website at www.codereonline.com. Dial-in details for the conference call as well as the audio webcast registration link are accessible in the Events & Presentations section of the same website. A recording of the webcast will be available following the conference call.
About Codere Online
Codere Online refers, collectively, to Codere Online Luxembourg, S.A. and its subsidiaries. Codere Online launched in 2014 as part of the renowned casino operator Codere Group. Codere Online offers online sports betting and online casino through its state-of-the art website and mobile applications. Codere currently operates in its core markets of Spain, Mexico, Colombia, Panama and Argentina. Codere Online’s online business is complemented by Codere Group’s physical presence throughout Latin America, forming the foundation of the leading omnichannel gaming and casino presence.
About Codere Group Codere Group is a multinational group devoted to entertainment and leisure. It is a leading player in the private gaming industry, with four decades of experience and with presence in seven countries in Europe (Spain and Italy) and Latin America (Argentina, Colombia, Mexico, Panama, and Uruguay).
Contacts:
Investors and Media Guillermo Lancha Director, Investor Relations and Communications Guillermo.Lancha@codere.com (+34)-628-928-152
BRENTWOOD, Tenn., July 10, 2025 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (the Company) announced today that it will release its 2025 second quarter financial results after the market closes on Wednesday, August 6, 2025. A live broadcast of CoreCivic’s conference call will begin at 10:00 a.m. central time (11:00 a.m. eastern time) on Thursday, August 7, 2025.
Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique passcode.
Participants may access the audio-only webcast of the conference call from the Company’s website at www.corecivic.com under the “Events & Presentations” section of the “Investors” page. A replay of the webcast will be available for seven days.
About CoreCivic CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through high-quality corrections and detention management, a network of residential and non-residential alternatives to incarceration to help address America’s recidivism crisis, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and one of the largest operators of such facilities in the United States. We have been a flexible and dependable partner for government for more than 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.
Contact:
Investors: David Garfinkle – Chief Financial Officer – (615) 263-3008
Media: Steve Owen – Vice President, Communications – (615) 263-3107
BOTHELL, Wash., July 10, 2025 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for an oral presentation at the 9th International Calicivirus Conference being held September 7-11, 2025 in Banff, Alberta, Canada. Sam Lee, PhD, the Company’s President and co-CEO, will present “Oral Direct-Acting Antiviral CDI-988 for Norovirus Infection Prevention and Treatment: Mechanism of Action and Phase 1 Study Results” on September 11.
“This year’s Calicivirus Conference will bring together the world’s leading norovirus experts, making it the ideal venue to share our pan-viral protease inhibitor CDI-988 Phase 1 data and clinical development strategy,” said Dr. Lee. “Norovirus causes a highly contagious gastrointestinal illness, triggering severe vomiting and diarrhea, and has a substantial economic impact with a societal cost of approximately $60 billion each year globally according to the CDC. There is no approved vaccine or antiviral therapeutics for norovirus infection. We are encouraged by our molecule’s novel pan-viral activity against all noroviruses including GII.4 and GII.17 strains.”
Pan-Viral Inhibitor CDI-988 CDI-988 was designed and developed with Cocrystal’s proprietary structure-based platform technology as a broad-spectrum inhibitor to a highly conserved region in the active site of 3CL viral proteases. Based on a novel mechanism of action and superior broad-spectrum antiviral activity, CDI-988 represents a compelling first-in-class oral treatment for noroviruses, which are members of the calicivirus family, and for coronaviruses. Cocrystal has completed a single-center, randomized, double-blind, placebo-controlled Phase 1 study in healthy adults evaluating the safety, tolerability and pharmacokinetics of CDI-988, including a food effect cohort.
Structure-Based Platform Technology Cocrystal’s proprietary structural biology, along with its expertise in enzymology and medicinal chemistry, enable its development of novel antiviral agents. The Company’s platform provides a three-dimensional structure of inhibitor complexes at near-atomic resolution, providing immediate insight to guide structure activity relationships. This helps to identify novel binding sites and allows for a rapid turnaround of structural information through highly automated X-ray data processing and refinement. The goal of this technology is to facilitate the development of best-in-class antiviral therapies that have fast onset of action or shortened treatment time, are safe, well tolerated and easy to administer, and are effective against all viral subtypes that cause disease and have a high barrier to viral resistance.
About the Calicivirus Conference The International Calicivirus Conference is held every three years and unites scientists from across the globe who study calicivirus virology, evolution, pathogenesis, structural biology, diagnosis, epidemiology, treatment and prevention. The conference aims to foster open discussions, spark new collaborations and explore groundbreaking research. Delegates have the opportunity to engage with the latest advances in the field through state-of-the-art lectures, oral presentations and poster sessions.
About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential for the Company’s CDI-988 product candidate as a treatment for norovirus. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, our need for additional capital to fund our operations over the next 12 months, risks relating to our ability to obtain regulatory approval for and proceed with clinical trials including recruiting volunteers and procuring materials for such studies by our clinical research organizations and vendors, the results of such studies, our and our collaboration partners’ technology and software performing as expected, general risks arising from clinical studies, regulatory changes, and potential development of effective treatments and/or vaccines by competitors, potential mutations in a virus we are targeting that may result in variants that are resistant to a product candidate we develop, the impact of the Trump Administration’s policies and actions on regulation affecting the FDA and other healthcare agencies and potential staffing issues resulting therefrom, as well as other government actions such as tariffs which may cause delays or force us to incur additional costs to proceed without development programs. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2024. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
R&D Day Highlighted Science, Current Trials, Future Indications. We attended the Eledon R&D Day on July 9 to hear and evaluate the progress in tegoprubart development. The presentations focused on the current clinical indications in renal transplantation, islet cell transplantation, xenotransplants, and plans for liver and other solid organ transplants. Conference presentation dates for upcoming data announcements were also announced.
Phase 1b Data Update Is Planned For August. The Phase 1b open-label trial has been expanded to enroll up to 36 patients, an increase from the original 9 patients. Data is scheduled for presentation at the World Transplant Congress on August 9, 2025. Previous data presentations have included 13 patients. We expect to see follow-up data from more patients treated longer, with data from additional patients beyond the initial 12-month trial duration.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
View original content to download multimedia:
